Research letterResponse of alopecia areata of the beard to oral tofacitinib
References (5)
- et al.
Alopecia areata of the beard: a review of the literature
Am J Clin Dermatol
(2017) - et al.
Complete regrowth of beard hair with ruxolitinib in an alopecia universalis patient
Skin Appendage Disord
(2018)
There are more references available in the full text version of this article.
Cited by (10)
Treatment of alopecia areata of the beard with baricitinib
2023, Journal of the American Academy of DermatologyJanus Kinase Inhibitors in Dermatology: Part 1 — General Considerations and Applications in Vitiligo and Alopecia Areata
2021, Actas Dermo-SifiliograficasTreatment of Steroid-Resistant Beard-Restricted Alopecia Areata with Baricitinib
2024, SKIN: Journal of Cutaneous MedicineTreatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review
2023, Dermatology and TherapyThe dermatologist’s guide to beards: a review of structure, function, care and pathology
2023, Clinical and Experimental DermatologyBeard Alopecia: An Updated and Comprehensive Review of Etiologies, Presentation and Treatment
2023, Journal of Clinical Medicine
Funding sources: Dr Bhoyrul was supported by The Geoffrey Dowling Fellowship from the British Association of Dermatologists.
Disclosure: Dr Sinclair has professional services associated with Leo Pharma, Amgen, Novartis, Merck & Co, Celgene, Coherus BioSciences, Janssen, Regeneron, MedImmune, GlaxoSmithKline, Cutanea, Samson Clinical, Boehringer Ingelheim, Pfizer, MSD, Oncobiologics, Roche, Eli Lilly, Bayer, and Sun Pharma. Ms Kerkemeyer, Mr John, and Mr Bhoyrul have no conflicts of interest to declare.
IRB approval status: Not applicable.
© 2019 by the American Academy of Dermatology, Inc.